Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Terminated 5Withdrawn 3Unknown 3Recruiting 3Completed 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × OTHER × ceritinib × Clear all
NCT02780128 2026-03-10

NEPENTHE

Children's Hospital of Philadelphia

Phase 1 Terminated
66 enrolled
CNS

Neoplasms, Neuroblastoma

NCT02513667 2023-02-03

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
14 enrolled 12 charts
Thoracic

ALK-positive Non-small Cell Lung Cancer

NCT03087448 2022-12-27

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

University of California, San Francisco

Phase 1 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

NCT02374489 2018-04-05

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

National Health Research Institutes, Taiwan

Phase 2 Terminated
9 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡